Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SCYNEXIS INCSCYX · Entity 7194 | Director | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SCYNEXIS INC
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,625 |
Reported balance
After 2026-06-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 2,875 · Balance 12,625 F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. F2: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2036-06-25 | Direct | 2,875 |
Reported balance
After 2026-06-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-26 · Grant · Acquired 2,875 · Balance 2,875 F3: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
F2: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
F3: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TETRAPHASE PHARMACEUTICALS INC
Report date July 28, 2020 · Filed July 29, 2020
Section 16 reporting ended · disclosed 2020-07-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-28 transaction · row 1
1 source rowRow 1 · 2020-07-28 · Other · Disposed 15,703.4 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) 2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) 2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 30, 2026 20:08 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 2,875 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001296998-26-000002 · ownership.xml · derivative · entry 2 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,875 Underlying: Common Stock · 2,875 shares Expires 2036-06-25 F3 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 20:08 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 2,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001296998-26-000002 · ownership.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,625 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. F2 · balance_after: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:18 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 23,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000950170-25-091598 · ownership.xml · derivative · entry 2 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2035-06-25 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:18 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-091598 · ownership.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:12 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 23,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000950170-24-076242 · ownership.xml · derivative · entry 2 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-19 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:12 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076242 · ownership.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 23:55 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-23-029031 · ownership.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 15, 2023 Filed Jun 23, 2023 20:05 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-029604 · ownership.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:07 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001209191-22-038669 · doc4.xml · derivative · entry 2 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-16 F2 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:07 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038669 · doc4.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 F1 · shares: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 12:31 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001209191-21-041825 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:09 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock Warrant · Derivative | 4,000 | Not disclosed Strike: $8.25 | Not disclosed |
DisclosureSEC source: 0001209191-20-064958 · doc4.xml · derivative · entry 3 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2024-06-21 F1 · price: Reflects the purchase on December 21, 2020 of 8,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:09 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock Warrant · Derivative | 4,000 | Not disclosed Strike: $7.33 | Not disclosed |
DisclosureSEC source: 0001209191-20-064958 · doc4.xml · derivative · entry 2 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2021-12-21 F1 · price: Reflects the purchase on December 21, 2020 of 8,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:09 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 8,000 | $6.25 | $50,000.00 |
DisclosureSEC source: 0001209191-20-064958 · doc4.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · price: Reflects the purchase on December 21, 2020 of 8,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 20:18 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | OtherCommon Stock | 15,703.4 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-020624 · doc4.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) 2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:11 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-20-041741 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-07-05 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| July 06, 2020 Filed Mar 31, 2021 20:04 UTC Amendment | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-21-023764 · doc4a.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-07-05 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 22:10 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | SaleCommon Stock | 5,734.65 | $2.25 | $12,902.96 |
DisclosureSEC source: 0001209191-19-059734 · doc4.xml · nonDerivative · entry 2 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250.4 F1 · shares: The number of shares of common stock reported on this Form 4 reflects a 1-for -20 reverse stock split effected on September 26, 2019. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $2.25 to $2.29 per share. The reporting person herby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission,the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 22:10 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | SaleCommon Stock | 1,870.35 | $2.34 | $4,376.62 |
DisclosureSEC source: 0001209191-19-059734 · doc4.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,985.05 F1 · shares: The number of shares of common stock reported on this Form 4 reflects a 1-for -20 reverse stock split effected on September 26, 2019. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $2.34 to $2.35 per share. The reporting person herby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission,the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 17:35 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001209191-19-038198 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-06-17 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 23:03 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantRestricted Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004605 · doc4.xml · derivative · entry 4 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration. F4 · derivative.exercise_date: The restricted stock units vest in three equal installments on each of January 17, 2020, January 17, 2021 and January 17, 2022. F4 · derivative.expiration_date: The restricted stock units vest in three equal installments on each of January 17, 2020, January 17, 2021 and January 17, 2022. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 23:03 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004605 · doc4.xml · derivative · entry 3 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration. F3 · derivative.exercise_date: These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on various dates beginning no earlier than March 1, 2020 and ending no later than March 1, 2022. F3 · derivative.expiration_date: These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on various dates beginning no earlier than March 1, 2020 and ending no later than March 1, 2022. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 13:09 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-19-001640 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-01-01 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| November 14, 2018 Filed Jan 18, 2019 23:03 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantCommon Stock | 3,332 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-004605 · doc4.xml · nonDerivative · entry 2 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,396 F1 · shares: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. F1 · price: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 18:53 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock option (right to buy) · Derivative | 21,595 | $0.79 Strike: $1.22 | $17,060.05 |
DisclosureSEC source: 0001209191-18-053681 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,595 Underlying: Common Stock · 21,595 shares Expires 2028-09-30 F1 · price: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 17:37 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock option (right to buy) · Derivative | 15,589 | $1.10 Strike: $1.69 | $17,147.90 |
DisclosureSEC source: 0001209191-18-040675 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,589 Underlying: Common Stock · 15,589 shares Expires 2028-07-01 F1 · price: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy. Read SEC document |
| May 14, 2018 Filed Jan 18, 2019 23:03 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantCommon Stock | 2,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-004605 · doc4.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,064 F1 · shares: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. F1 · price: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 23:13 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock option (right to buy) · Derivative | 19,959 | $0.86 Strike: $1.32 | $17,164.74 |
DisclosureSEC source: 0001209191-18-023923 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,959 Underlying: Common Stock · 19,959 shares Expires 2028-04-01 F1 · price: Stock option received by the Reporting Person pursuant to such Reporting Person's election to receive stock option in lieu of the Reporting Person's annual cash retainers (paid quarterly) under the Compensation Arrangement with Non-Employee Directors policy. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:06 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-023588 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration. F2 · derivative.exercise_date: The restricted stock units vest in two equal installments on each of April 2, 2019 and April 2, 2020. F2 · derivative.expiration_date: The restricted stock units vest in two equal installments on each of April 2, 2019 and April 2, 2020. Read SEC document |
| January 19, 2018 Filed Jan 20, 2018 00:44 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $6.34 | $0.00 |
DisclosureSEC source: 0001209191-18-004652 · doc4.xml · derivative · entry 4 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-01-18 F4 · derivative.exercise_date: Vests as to 6.25% of the shares on 4/19/2018 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/19/2022. Read SEC document |
| January 19, 2018 Filed Jan 20, 2018 00:44 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-004652 · doc4.xml · derivative · entry 3 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration. F3 · derivative.exercise_date: These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on January 31, 2021. F3 · derivative.expiration_date: These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on January 31, 2021. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:25 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 11,555 | $1.48 Strike: $2.28 | $17,101.40 |
DisclosureSEC source: 0001209191-18-001742 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,555 Underlying: Common Stock · 11,555 shares Expires 2028-01-01 F1 · price: This option was issued to the Reporting Person pursuant to the Issuer's Compensation Arrangement with Non-Employee Directors policy in lieu of the Reporting Person's annual cash retainers (paid quarterly) under such policy. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:23 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 19,989 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001209191-18-001741 · doc4.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,989 Underlying: Common Stock · 19,989 shares Expires 2028-01-01 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| November 14, 2017 Filed Jan 20, 2018 00:44 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantCommon Stock | 1,566 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-004652 · doc4.xml · nonDerivative · entry 2 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,006 F1 · shares: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. F1 · price: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:29 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 10,709 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001178253-17-000022 · wf-form4_150714892902213.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,709 Underlying: Common Stock · 10,709 shares Expires 2027-10-02 Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 19:55 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 14,396 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001178253-17-000013 · wf-form4_149928450673911.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,396 Underlying: Common Stock · 14,396 shares Expires 2027-07-03 Read SEC document |
| May 12, 2017 Filed Jan 20, 2018 00:44 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantCommon Stock | 3,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-004652 · doc4.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,440 F1 · shares: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. F1 · price: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 18:39 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 9,941 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001178253-17-000003 · wf-form4_149133115837413.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,941 Underlying: Common Stock · 9,941 shares Expires 2027-04-03 Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:44 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,378 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-17-010044 · doc4.xml · derivative · entry 2 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,378 shares Expires 2017-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are fully vested. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:44 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | Exercise / conversionCommon Stock | 30,378 | $2.90 | $88,096.20 |
DisclosureSEC source: 0001209191-17-010044 · doc4.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 23:13 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001209191-17-006850 · doc4.xml · derivative · entry 3 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-01-30 F4 · derivative.exercise_date: Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/31/2021. Read SEC document |
| January 31, 2017 Filed Feb 1, 2017 23:13 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantRestricted Stock Unit · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006850 · doc4.xml · derivative · entry 2 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration. F3 · derivative.exercise_date: These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on January 31, 2020. F3 · derivative.expiration_date: These restricted stock units shall be eligible to vest upon achievement of certain performance conditions and, if such conditions are met, shall vest on January 31, 2020. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 23:15 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 7,749 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001628280-17-000106 · wf-form4_148365813609367.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,749 Underlying: Common Stock · 7,749 shares Expires 2027-01-03 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 23:15 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 14,499 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001628280-17-000104 · wf-form4_148365810445622.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,499 Underlying: Common Stock · 14,499 shares Expires 2027-01-03 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document |
| November 14, 2016 Filed Feb 1, 2017 23:13 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantCommon Stock | 3,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-006850 · doc4.xml · nonDerivative · entry 1 Macdonald Guy · CIK 0001296998 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,961 F1 · shares: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. F1 · price: These shares were purchased pursuant to the issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 20:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 6,255 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001628280-16-019924 · wf-form4_147561128794846.xml · derivative · entry 1 Macdonald Guy · CIK 0001296998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,255 Underlying: Common Stock · 6,255 shares Expires 2026-10-03 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.